19 June 2017

Notice of Results
Analyst briefing

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces they will issue their preliminary results for the year ending 31 March 2017 on Tuesday, 11 July 2017.

A briefing for analysts will take place at the offices of Walbrook PR, 4 Lombard Street, London EC3V 9HD at 9.30am on Tuesday, 11 July 2017.

If you would like to register to attend or require further information, please contact Walbrook PR on 020 7933 8780 or email collagen@walbrookpr.com.

About Collagen Solutions:

Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic, an osteochondral scaffold for repairing cartilage defects in the knee. The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.

 

Enquiries: 

Collagen Solutions Plc Contact via Walbrook
Jamal Rushdy, Chief Executive Officer
Gill Black, Chief Financial Officer
 
   
Cenkos Securities plc (Nominated Adviser and Broker)
Stephen Keys
Steve Cox 
Tel: 0207 397 8900
   
Walbrook PR
Anna Dunphy
Mike Wort
Tel: 020 7933 8780 or collagen@walbrookpr.com
Mob: 07876 741 001
Mob: 07900 608 002